探索PET成像的纵向变化是否可以作为僵硬者综合征谱系障碍的生物标志物。

IF 3.9 2区 医学 Q1 CLINICAL NEUROLOGY
Munther M Queisi, Samantha N Roman, Mohammad S Sadaghiani, Lilja B Solnes, Scott D Newsome
{"title":"探索PET成像的纵向变化是否可以作为僵硬者综合征谱系障碍的生物标志物。","authors":"Munther M Queisi, Samantha N Roman, Mohammad S Sadaghiani, Lilja B Solnes, Scott D Newsome","doi":"10.1002/acn3.70145","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To identify metabolic patterns in the brain and musculoskeletal system of stiff person syndrome spectrum disorders (SPSD) patients over time using PET imaging and evaluate the impact of immune therapy on metabolic activity as a surrogate for treatment response.</p><p><strong>Methods: </strong>This observational study at the Johns Hopkins SPS Center of Excellence included adults (≥ 18 years) diagnosed with classic SPS, partial SPS, SPS plus, or PERM, who were treated from 2009 to 2023. Participants underwent at least two whole-body and/or dedicated brain PET scans. Brain PET analysis utilized NeuroQ v3.8 software to generate standardized Z-scores for 47 distinct brain regions, assessed by expert nuclear medicine radiologists. Patient demographics, antibody types, immune therapies, and symptomatic treatments were assessed.</p><p><strong>Results: </strong>Eighteen patients met inclusion criteria (10 SPS plus, 6 classic SPS, 2 PERM), with a mean age of 50.7 (SD 8.5) years; 77.8% were female and 50.0% were Black/African American. Hypermetabolic activity and hypometabolism were both seen over time in the brain and the musculoskeletal system. Two patients starting immune therapy in between PET scans demonstrated improvement in brain but not body PET findings.</p><p><strong>Interpretation: </strong>The study findings indicate that PET imaging abnormalities are present over time and appear to have regional patterns that are common among phenotypes. Additionally, starting immune therapy between scans appears to correlate with stabilization or improvement in brain PET abnormalities, though this was less clear in body PET scans. PET scans have the potential to be an imaging biomarker in SPSD, but future studies are needed to validate this.</p>","PeriodicalId":126,"journal":{"name":"Annals of Clinical and Translational Neurology","volume":" ","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Exploring if Longitudinal Changes on PET Imaging Can Serve as a Biomarker for Stiff Person Syndrome Spectrum Disorders.\",\"authors\":\"Munther M Queisi, Samantha N Roman, Mohammad S Sadaghiani, Lilja B Solnes, Scott D Newsome\",\"doi\":\"10.1002/acn3.70145\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To identify metabolic patterns in the brain and musculoskeletal system of stiff person syndrome spectrum disorders (SPSD) patients over time using PET imaging and evaluate the impact of immune therapy on metabolic activity as a surrogate for treatment response.</p><p><strong>Methods: </strong>This observational study at the Johns Hopkins SPS Center of Excellence included adults (≥ 18 years) diagnosed with classic SPS, partial SPS, SPS plus, or PERM, who were treated from 2009 to 2023. Participants underwent at least two whole-body and/or dedicated brain PET scans. Brain PET analysis utilized NeuroQ v3.8 software to generate standardized Z-scores for 47 distinct brain regions, assessed by expert nuclear medicine radiologists. Patient demographics, antibody types, immune therapies, and symptomatic treatments were assessed.</p><p><strong>Results: </strong>Eighteen patients met inclusion criteria (10 SPS plus, 6 classic SPS, 2 PERM), with a mean age of 50.7 (SD 8.5) years; 77.8% were female and 50.0% were Black/African American. Hypermetabolic activity and hypometabolism were both seen over time in the brain and the musculoskeletal system. Two patients starting immune therapy in between PET scans demonstrated improvement in brain but not body PET findings.</p><p><strong>Interpretation: </strong>The study findings indicate that PET imaging abnormalities are present over time and appear to have regional patterns that are common among phenotypes. Additionally, starting immune therapy between scans appears to correlate with stabilization or improvement in brain PET abnormalities, though this was less clear in body PET scans. PET scans have the potential to be an imaging biomarker in SPSD, but future studies are needed to validate this.</p>\",\"PeriodicalId\":126,\"journal\":{\"name\":\"Annals of Clinical and Translational Neurology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2025-08-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Clinical and Translational Neurology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/acn3.70145\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Clinical and Translational Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/acn3.70145","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:利用PET成像技术识别僵人综合征谱系障碍(SPSD)患者的脑和肌肉骨骼系统随时间的代谢模式,并评估免疫治疗对代谢活动的影响,作为治疗反应的替代指标。方法:这项观察性研究在约翰霍普金斯SPS卓越中心进行,纳入了2009年至2023年接受治疗的诊断为典型SPS、部分SPS、SPS +或PERM的成年人(≥18岁)。参与者接受了至少两次全身和/或专门的脑部PET扫描。脑PET分析使用NeuroQ v3.8软件生成47个不同大脑区域的标准化z分数,由核医学放射科专家评估。评估患者人口统计学、抗体类型、免疫疗法和对症治疗。结果:18例患者符合纳入标准(SPS + 10例,经典SPS 6例,PERM 2例),平均年龄50.7岁(SD 8.5);77.8%为女性,50.0%为黑人/非裔美国人。随着时间的推移,在大脑和肌肉骨骼系统中都可以看到高代谢活动和低代谢。在PET扫描之间开始免疫治疗的两名患者显示大脑改善,但身体PET检查结果没有改善。解释:研究结果表明,PET成像异常随着时间的推移而存在,并且似乎具有在表型中常见的区域模式。此外,在扫描之间开始免疫治疗似乎与脑部PET异常的稳定或改善有关,尽管这在身体PET扫描中不太清楚。PET扫描有可能成为SPSD的成像生物标志物,但需要进一步的研究来验证这一点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Exploring if Longitudinal Changes on PET Imaging Can Serve as a Biomarker for Stiff Person Syndrome Spectrum Disorders.

Objective: To identify metabolic patterns in the brain and musculoskeletal system of stiff person syndrome spectrum disorders (SPSD) patients over time using PET imaging and evaluate the impact of immune therapy on metabolic activity as a surrogate for treatment response.

Methods: This observational study at the Johns Hopkins SPS Center of Excellence included adults (≥ 18 years) diagnosed with classic SPS, partial SPS, SPS plus, or PERM, who were treated from 2009 to 2023. Participants underwent at least two whole-body and/or dedicated brain PET scans. Brain PET analysis utilized NeuroQ v3.8 software to generate standardized Z-scores for 47 distinct brain regions, assessed by expert nuclear medicine radiologists. Patient demographics, antibody types, immune therapies, and symptomatic treatments were assessed.

Results: Eighteen patients met inclusion criteria (10 SPS plus, 6 classic SPS, 2 PERM), with a mean age of 50.7 (SD 8.5) years; 77.8% were female and 50.0% were Black/African American. Hypermetabolic activity and hypometabolism were both seen over time in the brain and the musculoskeletal system. Two patients starting immune therapy in between PET scans demonstrated improvement in brain but not body PET findings.

Interpretation: The study findings indicate that PET imaging abnormalities are present over time and appear to have regional patterns that are common among phenotypes. Additionally, starting immune therapy between scans appears to correlate with stabilization or improvement in brain PET abnormalities, though this was less clear in body PET scans. PET scans have the potential to be an imaging biomarker in SPSD, but future studies are needed to validate this.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Annals of Clinical and Translational Neurology
Annals of Clinical and Translational Neurology Medicine-Neurology (clinical)
CiteScore
9.10
自引率
1.90%
发文量
218
审稿时长
8 weeks
期刊介绍: Annals of Clinical and Translational Neurology is a peer-reviewed journal for rapid dissemination of high-quality research related to all areas of neurology. The journal publishes original research and scholarly reviews focused on the mechanisms and treatments of diseases of the nervous system; high-impact topics in neurologic education; and other topics of interest to the clinical neuroscience community.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信